• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

OSE Immunotherapeutics

Parachute over a desert
Biotech

BioNTech founders to pioneer new company—Chutes & Ladders

BioNTech founders will depart to pioneer new company. OSE makes interim CEO permanent. Ipsen adds former Alltrna CEO as North America leader.
Darren Incorvaia , Zoey Becker , Will Maddox Mar 13, 2026 8:30am
two baskets of eggs on a farm

Boehringer axes MASH deal after OSE asset fails to show efficacy

Mar 2, 2026 2:16pm
reshuffle pipeline target reorganize shift change

Ose narrows focus to conserve cash at expense of wider pipeline

Dec 9, 2025 9:41am
A ballpoint pen rests on top of a stack of documents ready for signing

AbbVie hands back phase 1 duties for inflammation drug to Ose

Dec 8, 2025 5:39am
parachute mountains sunset clouds

Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders

Oct 10, 2025 8:30am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings